共 1659 条
[121]
Mortier E(2011)Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype Clin Cancer Res 17 5822-2381
[122]
Melchior A(2014)Collagen signaling enhances tumor progression after anti-VEGF therapy in a murine model of pancreatic ductal adenocarcinoma Cancer Res 74 1032-2684
[123]
Degeest G(2017)Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK Br J Cancer 116 609-2111
[124]
Geeraerts A(2017)MicroRNA-155 controls exosome synthesis and promotes gemcitabine resistance in pancreatic ductal adenocarcinoma Sci Rep 7 42339-72
[125]
Ivarsson Y(2006)Cellular pharmacology of gemcitabine Ann Oncol 17 v7-227
[126]
Depoortere F(2007)Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development Proc Natl Acad Sci USA 104 16170-738
[127]
Coomans C(2001)Stem cells, cancer, and cancer stem cells Nature 414 105-889
[128]
Vermeiren E(2020)Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210 Cell Oncol (Dordr) 43 123-3258
[129]
Mittelbrunn M(2021)Targeting hypoxic tumor microenvironment in pancreatic cancer J Hematol Oncol 14 14-1061.e1018
[130]
Vicente Manzanares M(2016)Neutral sphingomyelinase (SMPD3) deficiency disrupts the Golgi secretory pathway and causes growth inhibition Cell Death Dis 7 e2488-3610